A Review of the Efficacy of Topical Statins for Treating Disseminated Superficial Actinic Porokeratosis. Ghani, H., Richards, E., Truong, T. M., Rao, B. K., & Zhang, A. Journal of drugs in dermatology: JDD, 22(10):1053–1057, October, 2023. doi abstract bibtex Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range from asymptomatic to pruritic circular pink to brown macules, papules, or plaques surrounded by a raised border. DSAP carries about 7.5-10% risk of malignant transformation to SCC or BCC. While in the past DSAP has been widely treated with topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-fluorouracil, imiquimod, photodynamic therapy, retinoids, cryotherapy, and laser therapy, these therapies have shown limited efficacy and have caused adverse effects including inflammatory reactions, hyperpigmentation, pain, and erythema. Recently, a formulation of topical statin and cholesterol has surfaced as a new and promising treatment for DSAP which has shown clinical improvement with a tolerable adverse effect profile when compared to the current therapies. Of the 8 case studies with a total of 20 patients with DSAP, 90% (18/20) reported clinical improvement with various forms of topical statin therapy. While promising, larger randomized controlled trials are needed to evaluate the long-term use of topical statins for DSAP. J Drugs Dermatol. 2023;22(10): doi:10.36849/JDD.7540.
@article{ghani_review_2023,
title = {A {Review} of the {Efficacy} of {Topical} {Statins} for {Treating} {Disseminated} {Superficial} {Actinic} {Porokeratosis}},
volume = {22},
issn = {1545-9616},
doi = {10.36849/JDD.7540},
abstract = {Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range from asymptomatic to pruritic circular pink to brown macules, papules, or plaques surrounded by a raised border. DSAP carries about 7.5-10\% risk of malignant transformation to SCC or BCC. While in the past DSAP has been widely treated with topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-fluorouracil, imiquimod, photodynamic therapy, retinoids, cryotherapy, and laser therapy, these therapies have shown limited efficacy and have caused adverse effects including inflammatory reactions, hyperpigmentation, pain, and erythema. Recently, a formulation of topical statin and cholesterol has surfaced as a new and promising treatment for DSAP which has shown clinical improvement with a tolerable adverse effect profile when compared to the current therapies. Of the 8 case studies with a total of 20 patients with DSAP, 90\% (18/20) reported clinical improvement with various forms of topical statin therapy. While promising, larger randomized controlled trials are needed to evaluate the long-term use of topical statins for DSAP. J Drugs Dermatol. 2023;22(10):\ \ \ doi:10.36849/JDD.7540.},
language = {eng},
number = {10},
journal = {Journal of drugs in dermatology: JDD},
author = {Ghani, Hira and Richards, Elizabeth and Truong, Thu M. and Rao, Babar K. and Zhang, Alice},
month = oct,
year = {2023},
pmid = {37801522},
keywords = {Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Imiquimod, Photochemotherapy, Porokeratosis, Retinoids},
pages = {1053--1057},
}
Downloads: 0
{"_id":"Qx3dSZuidasymJFJE","bibbaseid":"ghani-richards-truong-rao-zhang-areviewoftheefficacyoftopicalstatinsfortreatingdisseminatedsuperficialactinicporokeratosis-2023","author_short":["Ghani, H.","Richards, E.","Truong, T. M.","Rao, B. K.","Zhang, A."],"bibdata":{"bibtype":"article","type":"article","title":"A Review of the Efficacy of Topical Statins for Treating Disseminated Superficial Actinic Porokeratosis","volume":"22","issn":"1545-9616","doi":"10.36849/JDD.7540","abstract":"Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range from asymptomatic to pruritic circular pink to brown macules, papules, or plaques surrounded by a raised border. DSAP carries about 7.5-10% risk of malignant transformation to SCC or BCC. While in the past DSAP has been widely treated with topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-fluorouracil, imiquimod, photodynamic therapy, retinoids, cryotherapy, and laser therapy, these therapies have shown limited efficacy and have caused adverse effects including inflammatory reactions, hyperpigmentation, pain, and erythema. Recently, a formulation of topical statin and cholesterol has surfaced as a new and promising treatment for DSAP which has shown clinical improvement with a tolerable adverse effect profile when compared to the current therapies. Of the 8 case studies with a total of 20 patients with DSAP, 90% (18/20) reported clinical improvement with various forms of topical statin therapy. While promising, larger randomized controlled trials are needed to evaluate the long-term use of topical statins for DSAP. J Drugs Dermatol. 2023;22(10): doi:10.36849/JDD.7540.","language":"eng","number":"10","journal":"Journal of drugs in dermatology: JDD","author":[{"propositions":[],"lastnames":["Ghani"],"firstnames":["Hira"],"suffixes":[]},{"propositions":[],"lastnames":["Richards"],"firstnames":["Elizabeth"],"suffixes":[]},{"propositions":[],"lastnames":["Truong"],"firstnames":["Thu","M."],"suffixes":[]},{"propositions":[],"lastnames":["Rao"],"firstnames":["Babar","K."],"suffixes":[]},{"propositions":[],"lastnames":["Zhang"],"firstnames":["Alice"],"suffixes":[]}],"month":"October","year":"2023","pmid":"37801522","keywords":"Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Imiquimod, Photochemotherapy, Porokeratosis, Retinoids","pages":"1053–1057","bibtex":"@article{ghani_review_2023,\n\ttitle = {A {Review} of the {Efficacy} of {Topical} {Statins} for {Treating} {Disseminated} {Superficial} {Actinic} {Porokeratosis}},\n\tvolume = {22},\n\tissn = {1545-9616},\n\tdoi = {10.36849/JDD.7540},\n\tabstract = {Porokeratosis is a rare group of acquired or hereditary dermatoses characterized by linear or annular plaques with a keratotic border. DSAP is the most common porokeratosis, and lesions range from asymptomatic to pruritic circular pink to brown macules, papules, or plaques surrounded by a raised border. DSAP carries about 7.5-10\\% risk of malignant transformation to SCC or BCC. While in the past DSAP has been widely treated with topical diclofenac, ingenol mebutate, topical vitamin D analog, 5-fluorouracil, imiquimod, photodynamic therapy, retinoids, cryotherapy, and laser therapy, these therapies have shown limited efficacy and have caused adverse effects including inflammatory reactions, hyperpigmentation, pain, and erythema. Recently, a formulation of topical statin and cholesterol has surfaced as a new and promising treatment for DSAP which has shown clinical improvement with a tolerable adverse effect profile when compared to the current therapies. Of the 8 case studies with a total of 20 patients with DSAP, 90\\% (18/20) reported clinical improvement with various forms of topical statin therapy. While promising, larger randomized controlled trials are needed to evaluate the long-term use of topical statins for DSAP. J Drugs Dermatol. 2023;22(10):\\ \\ \\ doi:10.36849/JDD.7540.},\n\tlanguage = {eng},\n\tnumber = {10},\n\tjournal = {Journal of drugs in dermatology: JDD},\n\tauthor = {Ghani, Hira and Richards, Elizabeth and Truong, Thu M. and Rao, Babar K. and Zhang, Alice},\n\tmonth = oct,\n\tyear = {2023},\n\tpmid = {37801522},\n\tkeywords = {Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Imiquimod, Photochemotherapy, Porokeratosis, Retinoids},\n\tpages = {1053--1057},\n}\n\n\n\n","author_short":["Ghani, H.","Richards, E.","Truong, T. M.","Rao, B. K.","Zhang, A."],"key":"ghani_review_2023","id":"ghani_review_2023","bibbaseid":"ghani-richards-truong-rao-zhang-areviewoftheefficacyoftopicalstatinsfortreatingdisseminatedsuperficialactinicporokeratosis-2023","role":"author","urls":{},"keyword":["Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Imiquimod","Photochemotherapy","Porokeratosis","Retinoids"],"metadata":{"authorlinks":{}},"downloads":0},"bibtype":"article","biburl":"https://bibbase.org/zotero/raoresearch","dataSources":["aGgndugSyribdb2rd"],"keywords":["humans","hydroxymethylglutaryl-coa reductase inhibitors","imiquimod","photochemotherapy","porokeratosis","retinoids"],"search_terms":["review","efficacy","topical","statins","treating","disseminated","superficial","actinic","porokeratosis","ghani","richards","truong","rao","zhang"],"title":"A Review of the Efficacy of Topical Statins for Treating Disseminated Superficial Actinic Porokeratosis","year":2023}